医学
产后
入射(几何)
肝炎
乙型肝炎
怀孕
戒毒
药品
内科学
拉米夫定
乙型肝炎病毒
妊娠期
肝病学
免疫学
病毒
药理学
物理
光学
生物
遗传学
作者
Minghui Li,Fangfang Sun,Xiaoyue Bi,Yanjie Lin,Yang Liu,Tingting Jiang,Wen Deng,Yao Lu,Lu Zhang,Wei Yi,Yao Xie
标识
DOI:10.1007/s12072-022-10412-w
摘要
ObjectiveTo investigate the effect of antiviral therapy and drug withdrawal on the incidence of hepatitis B after delivery in pregnant women with chronic hepatitis B virus (CHB) infection who received tenofovir disoproxil fumarate (TDF) treatment.MethodsEligible CHB pregnant women were enrolled, and received TDF at 32 weeks gestation. The drug was stopped immediately or at 6 weeks after delivery. The HBV biomarkers and clinical biochemical parameters were monitored during gestation and 24 weeks after delivery.ResultsThere were 264 women completed the observation, including 96 untreated subjects in control group. Among 168 treated subjects, 131 cases stopped drug immediately after delivery and 37 cases delayed the drug withdrawal at 6 weeks after delivery. The incidence of postpartum hepatitis in control, immediate drug withdrawal, and delayed drug withdrawal were 28.1% (27/96), 23.7% (31/131), and 24.3% (9/37), showing no significant difference (χ2 = 0.607, p = 0.738). No factor was found to be associated with the occurrence of postpartum hepatitis. It’s noteworthy that 96.3% of postpartum hepatitis in control group and 92.3% of postpartum hepatitis in immediate drug withdrawal group occurred within 12 weeks after delivery. While in delayed drug withdrawal group, the rate of postpartum hepatitis occurred within 12 weeks after delivery was 77.7%.ConclusionWithdrawing antiviral drug immediately or at 6 weeks after delivery did not affect the incidence of postpartum hepatitis in CHB women, but delaying drug withdrawal might delay the onset of postpartum hepatitis.Clinical trial registration number: NCT03214302.
科研通智能强力驱动
Strongly Powered by AbleSci AI